Crestline Management, L.P. — Q3 2025 13F-HR

← Crestline Management, L.P.

Q3 2025 · 13F-HR

Crestline Management, L.P.holdings as filed

Filed 2025-11-14 · accession 0001315863-25-000800

$58.1M

Reported value

Positions

2025-09-30

Period end

View analyzed profile →PRO

The Brief · Crestline Management, L.P. · Q3 2025

AI · grounded in 13F

Crestline Management, L.P. established a new position in Denali Therapeutics Inc DNLI valued at $49.5M. The fund also initiated stakes in Sana Biotechnology Inc SANA and 8x8 Inc New EGHT for $6.5M and $2.1M, respectively. These three new holdings comprise the fund's total AUM of $58.1M.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
24823R105	DNLI	DENALI THERAPEUTICS INC	$49.5M	85.3%	3,410,732	Common	SOLE
799566104	SANA	SANA BIOTECHNOLOGY INC	$6.5M	11.1%	1,820,937	Common	SOLE
282914100	EGHT	8X8 INC NEW	$2.1M	3.62%	990,580	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.